NEW HAVEN, Conn.--(BUSINESS WIRE)--Nov 25, 2024--
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the Company will host a webcast to provide a program update on RLYB116, its innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases. The webcast will take place on Monday, December 2 at 8:30 AM Eastern Time and will review recent manufacturing process enhancements, biomarker characterization analyses, and the Company's future plans for the program.
kAmk6>m(6342DE x?7@C>2E:@?k^6>mk^Am kAm%96 =:G6 H6342DE >2J 36 2446DD65 3J G:D:E:?8 #2==J3:@'D H63D:E6 2E k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEATbpTauTau:?G6DE@CD]C2==J3:@]4@>U2>Aj6D966Eldc'df'cdU2>Aj?6HD:E6>:5la_ac''aa_'_df_U2>Aj=2?l6?\&$U2>Aj2?49@Cl9EEATbpTauTau:?G6DE@CD]C2==J3:@]4@>U2>Aj:?56Il'U2>Aj>5dl63633gf65heageb62f__45''ceh_5eg6Q C6=lQ?@7@==@HQ D92A6lQC64EQm9EEAi^^:?G6DE@CD]C2==J3:@]4@>k^2m] p C6A=2J 2?5 244@>A2?J:?8 D=:56D @7 E96 H6342DE H:== 36 2G2:=23=6 @? E96 #2==J3:@ H63D:E6 7@C b_ 52JD 7@==@H:?8 E96 6G6?E]k^AmkAmk6>mp3@FE #2==J3:@k^6>mk^AmkAm#2==J3:@ W}p$sp"i #{*qX :D 2 4=:?:42=\DE286 3:@E649?@=@8J 4@>A2?J H:E9 2 >:DD:@? E@ 56G6=@A 2?5 4@>>6C4:2=:K6 =:76\EC2?D7@C>:?8 E96C2A:6D 7@C A2E:6?ED H:E9 D6G6C6 2?5 C2C6 5:D62D6D] #2==J3:@ 92D 3F:=E 2 3C@25 A:A6=:?6 @7 AC@>:D:?8 AC@5F4E 42?5:52E6D 2:>65 2E 255C6DD:?8 5:D62D6D H:E9 F?>6E >65:42= ?665 :? 2C62D @7 >2E6C?2= 76E2= 962=E9[ 4@>A=6>6?E 5JDC68F=2E:@?[ 96>2E@=@8J[ 2?5 >6E23@=:4 5:D@C56CD] %96 r@>A2?J 92D EH@ 4=:?:42= DE286 AC@8C2>Di #{*qa'a[ 2? 2?E:\w!p\'2 2?E:3@5J 7@C E96 AC6G6?E:@? @7 76E2= 2?5 ?6@?2E2= 2==@:>>F?6 E9C@>3@4JE@A6?:2 Wu}px%X 2?5 #{*q''e[ 2 rd :?9:3:E@C E92E 92D E96 A@E6?E:2= E@ EC62E D6G6C2= 5:D62D6D @7 4@>A=6>6?E 5JDC68F=2E:@?[ 2D H6== 2D 255:E:@?2= AC@8C2>D :? AC64=:?:42= 56G6=@A>6?E] #2==J3:@ :D 9625BF2CE6C65 :? }6H w2G6?[ r@??64E:4FE] u@C >@C6 :?7@C>2E:@?[ A=62D6 G:D:E k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEATbpTauTauHHH]C2==J3:@]4@>TauU2>Aj6D966Eldc'df'cdU2>Aj?6HD:E6>:5la_ac''aa_'_df_U2>Aj=2?l6?\&$U2>Aj2?49@ClHHH]C2==J3:@]4@>U2>Aj:?56IlaU2>Aj>5dlaee53ab67bef75b4fbdf7'2a3_3b33h2Q C6=lQ?@7@==@HQ D92A6lQC64EQmHHH]C2==J3:@]4@>k^2m 2?5 7@==@H FD @? k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauHHH]=:?<65:?]4@>Tau4@>A2?JTauC2==J3:@TauU2>Aj6D966Eldc'df'cdU2>Aj?6HD:E6>:5la_ac''aa_'_df_U2>Aj=2?l6?\&$U2>Aj2?49@Cl{:?<65x?U2>Aj:?56IlbU2>Aj>5dl6aaa4'333e3c66gd_e254'_ag_b74ghdQ C6=lQ?@7@==@HQ D92A6lQC64EQm{:?<65x?k^2m 2?5 k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauEH:EE6C]4@>TauC2==J3:@U2>Aj6D966Eldc'df'cdU2>Aj?6HD:E6>:5la_ac''aa_'_df_U2>Aj=2?l6?\&$U2>Aj2?49@Cl%H:EE6CU2>Aj:?56IlcU2>Aj>5dl47fha_fb76'33ag36bh742hcd5__75d3Q C6=lQ?@7@==@HQ D92A6lQC64EQm%H:EE6Ck^2m]k^AmkAm':6H D@FC46 G6CD:@? @? k2 9C67lQ9EEAi^^3FD:?6DDH:C6]4@>Qm3FD:?6DDH:C6]4@>k^2mik2 9C67lQ9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac''aa_'_df_^6?^Q C6=lQ?@7@==@HQm9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac''aa_'_df_^6?^k^2mk^AmkAmr~}%pr%i x?G6DE@CDk^AmkAm$2>2?E92 %C24Jk^AmkAm#2==J3:@ r@CA@C2E:@?k^AmkAmWcfdX cf\#p{{* WtIE] agaXk^AmkAmk2 9C67lQ>2:=E@i:?G6DE@CDoC2==J3:@]4@>z6G:?Qm:?G6DE@CDoC2==J3:@]4@>z6G:?k^2m {F:k^AmkAm!C64:D:@? p"k^Am kAmWa'aX ehg\geh'k^AmkAmk2 9C67lQ>2:=E@i<6G:?]=F:oAC64:D:@?2B]4@>|65:2Qm<6G:?]=F:oAC64:D:@?2B]4@>|65:2k^2mk^AmkAm':4E@C:2 #6J?@=5Dk^AmkAm|:DD:@? }@CE9k^AmkAmWfe_X dfh\a'bck^AmkAmk2 9C67lQ>2:=E@iC2==J3:@o>:DD:@??@CE9]4@>QmC2==J3:@o>:DD:@??@CE9]4@>k^2mk^AmkAmzt*(~#si r~}}tr%xr&% &}x%ts $%p%t$ }~#%w p|t#xrpk^AmkAmx}s&$%#* zt*(~#si qx~%trw}~{~v* !wp#|prt&%xrp{ wtp{%wk^AmkAm$~&#rti #2==J3:@ r@CA@C2E:@?k^AmkAmr@AJC:89E qFD:?6DD (:C6 a_ac]k^AmkAm!&qi ''^ad^a_ac _gi__ p|^sx$ri ''^ad^a_ac _gi_a p|k^AmkAmk2 9C67lQ9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac''aa_'_df_^6?Qm9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac''aa_'_df_^6?k^2mk^Am